Abstract:Macrophages are a promising target for drug delivery to influence macrophage-associated processes in the body, namely due to the presence of resistant microorganisms in macrophages. In this work, a series of mannosylated carriers based on mannan, polyethylenimine (PEI) and cyclodextrin (CD) was synthesized. The molecular architecture was studied using FTIR and 1H NMR spectroscopy. The particle size, from small 10–50 nm to large 500 nm, depending on the type of carrier, is potentially applicable for the creation of various medicinal forms: intravenous, oral and inhalation. Non-specific capture by cells with a simultaneous increase in selectivity to CD206+ macrophages was achieved. ConA was used as a model mannose receptor, binding galactosylated (CD206 non-specific) carriers with constants of the order of 104 M−1 and mannosylated conjugates of 106–107 M−1. The results of such primary “ConA-screening” of ligands are in a good agreement in terms of the comparative effectiveness of the interaction of ligands with the CD206+ macrophages: non-specific (up to 10%) absorption of highly charged and small particles; weakly specific uptake of galactosylated polymers (up to 50%); and high affine capture (more than 70–80%) of the ligands with grafted trimannoside was demonstrated using the cytometry method. Double and multi-complexes of antibacterials (moxifloxacin with its adjuvants from the class of terpenoids) were proposed as enhanced forms against resistant pathogens. In vivo pharmacokinetic experiments have shown that polymeric carriers significantly improve the efficiency of the antibiotic: the half-life of moxifloxacin is increased by 2–3 times in conjugate-loaded forms, bio-distribution to the lungs in the first hours after administration of the drug is noticeably greater, and, after 4 h of observation, free moxifloxacin was practically removed from the lungs of rats. Although, in polymer systems, its content is significant—1.2 μg/g. Moreover, the importance of the covalent crosslinking carrier with mannose label was demonstrated. Thus, this paper describes experimental, scientifically based methods of targeted drug delivery to macrophages to create enhanced medicinal forms.

Macrophage Mannose Receptor-Specific Gene Delivery Vehicle for Macrophage Engineering.

Mannosylated Cationic Copolymers for Gene Delivery to Macrophages

Macrophage manufacturing and engineering with 5'-Cap1 and N1-methylpseudouridine-modified mRNA

Targeted Gene Delivery to Macrophages by Biodegradable Star-Shaped Polymers.

Mannosylated Systems for Targeted Delivery of Antibacterial Drugs to Activated Macrophages

Targeting Delivery Oligonucleotide into Macrophages by Cationic Polysaccharide from Bletilla Striata Successfully Inhibited the Expression of TNF-α

Specific Targeting, Imaging, and Ablation of Tumor-Associated Macrophages by Theranostic Mannose-AIEgen Conjugates.

Efficient gene delivery by multifunctional star poly (β-amino ester)s into difficult-to-transfect macrophages for M1 polarization

Rational Design of Advanced Gene Delivery Carriers: Macrophage Phenotype Matters

Hepatic-targeted Gene Delivery Using Cationic Mannan Vehicle.

Dimethylaminoethyl modified curdlan nanoparticles for targeted siRNA delivery to macrophages

Macrophage membrane biomimetic drug delivery system: for inflammation targeted therapy

Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy

Mannose/stearyl chloride doubly functionalized polyethylenimine as a nucleic acid vaccine carrier to promote macrophage uptake

Nanomedicine engulfed by macrophages for targeted tumor therapy

Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations

Exploiting Macrophages As Targeted Carrier to Guide Nanoparticles into Glioma

Producing Anti-Inflammatory Macrophages by Nanoparticle-Triggered Clustering of Mannose Receptors

Lyotropic Liquid Crystalline Phase Nanostructure and Cholesterol Enhance Lipid Nanoparticle Mediated mRNA Transfection in Macrophages

Augmented Cytotoxicity and Antigen Presenting Ability of Macrophages by Transfection with the M-CSF Or/and IFN-γ Gene

Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization